Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis

Hideaki Nakaya, Hiroyuki Sasamura, Yudai Kitamura, Tetsuro Amemiya, Konosuke Konishi, Matsuhiko Hayashi, Takao Saruta

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Angiotensin converting enzyme inhibitors (ACEI) are known to inhibit the progression of established renal failure. The aim of this study was to compare the efficacy of an ACEI and an AT1 receptor antagonist (AT1R-Ant) in preventing the development of renal disease, at an early stage of hypertensive nephrosclerosis. SHRSP/Izm rats (n = 61) were treated from 10 wk until 22 wk with the ACEI delapril (40 mg/kg/d) or the AT1R-Ant candesartan cilexetil (1 mg/kg/d). Proteinuria, and structural/ultrastructural changes were assessed at 14 and 22 wk. Treatment with either agent resulted in reductions in blood pressure and cardiovascular hypertrophy. Neither proteinuria nor major renal histological changes were evident at 14 wk. At 22 wk, however, proteinuria accompanied by nephrosclerotic changes was seen in the untreated SHRSP/Izm. Treatment with either ACEI or AT1R-Ant resulted in similar reductions in proteinuria (untreated, 32.2 ± 7.4; delapril-treated, 5.5 ± 1.2; candesartan-treated, 3.9 ± 0.3 mg/100 g/df. Prominent sclerosis of small-to-medium sized renal arteries was seen in the untreated SHRSP/Izm at 22 wk, but was similarly attenuated by the ACEI and AT1R-Ant. The glomerular ultrastructure was comparable between the two groups. No significant changes in renal AT1a or AT1b receptor subtype mRNA expression mere seen throughout the course of the study. In contrast, a decrease in AT2 receptor mRNA was seen in the drug-treated groups at 14 wk but not at 22 wk. These results suggest that both ACEI and AT1R-Ant have similar efficacy in attenuating the onset of renal injury in early hypertensive nephrosclerosis, and that treatment with either agent is associated with a transient decrease in AT2 receptor mRNA expression.

Original languageEnglish
Pages (from-to)303-312
Number of pages10
JournalHypertension Research - Clinical and Experimental
Volume22
Issue number4
Publication statusPublished - 1999

Fingerprint

Nephrosclerosis
Angiotensin Receptors
Angiotensins
Angiotensin-Converting Enzyme Inhibitors
Kidney
Proteinuria
Wounds and Injuries
Messenger RNA
Sclerosis
Renal Artery
Hypertrophy
Renal Insufficiency
Blood Pressure
Pharmaceutical Preparations

Keywords

  • Angiotensin
  • Nephrosclerosis
  • Receptor

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Nakaya, H., Sasamura, H., Kitamura, Y., Amemiya, T., Konishi, K., Hayashi, M., & Saruta, T. (1999). Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertension Research - Clinical and Experimental, 22(4), 303-312.

Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. / Nakaya, Hideaki; Sasamura, Hiroyuki; Kitamura, Yudai; Amemiya, Tetsuro; Konishi, Konosuke; Hayashi, Matsuhiko; Saruta, Takao.

In: Hypertension Research - Clinical and Experimental, Vol. 22, No. 4, 1999, p. 303-312.

Research output: Contribution to journalArticle

Nakaya, H, Sasamura, H, Kitamura, Y, Amemiya, T, Konishi, K, Hayashi, M & Saruta, T 1999, 'Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis', Hypertension Research - Clinical and Experimental, vol. 22, no. 4, pp. 303-312.
Nakaya, Hideaki ; Sasamura, Hiroyuki ; Kitamura, Yudai ; Amemiya, Tetsuro ; Konishi, Konosuke ; Hayashi, Matsuhiko ; Saruta, Takao. / Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. In: Hypertension Research - Clinical and Experimental. 1999 ; Vol. 22, No. 4. pp. 303-312.
@article{a1214172d4f14d489f364eb137d720ff,
title = "Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis",
abstract = "Angiotensin converting enzyme inhibitors (ACEI) are known to inhibit the progression of established renal failure. The aim of this study was to compare the efficacy of an ACEI and an AT1 receptor antagonist (AT1R-Ant) in preventing the development of renal disease, at an early stage of hypertensive nephrosclerosis. SHRSP/Izm rats (n = 61) were treated from 10 wk until 22 wk with the ACEI delapril (40 mg/kg/d) or the AT1R-Ant candesartan cilexetil (1 mg/kg/d). Proteinuria, and structural/ultrastructural changes were assessed at 14 and 22 wk. Treatment with either agent resulted in reductions in blood pressure and cardiovascular hypertrophy. Neither proteinuria nor major renal histological changes were evident at 14 wk. At 22 wk, however, proteinuria accompanied by nephrosclerotic changes was seen in the untreated SHRSP/Izm. Treatment with either ACEI or AT1R-Ant resulted in similar reductions in proteinuria (untreated, 32.2 ± 7.4; delapril-treated, 5.5 ± 1.2; candesartan-treated, 3.9 ± 0.3 mg/100 g/df. Prominent sclerosis of small-to-medium sized renal arteries was seen in the untreated SHRSP/Izm at 22 wk, but was similarly attenuated by the ACEI and AT1R-Ant. The glomerular ultrastructure was comparable between the two groups. No significant changes in renal AT1a or AT1b receptor subtype mRNA expression mere seen throughout the course of the study. In contrast, a decrease in AT2 receptor mRNA was seen in the drug-treated groups at 14 wk but not at 22 wk. These results suggest that both ACEI and AT1R-Ant have similar efficacy in attenuating the onset of renal injury in early hypertensive nephrosclerosis, and that treatment with either agent is associated with a transient decrease in AT2 receptor mRNA expression.",
keywords = "Angiotensin, Nephrosclerosis, Receptor",
author = "Hideaki Nakaya and Hiroyuki Sasamura and Yudai Kitamura and Tetsuro Amemiya and Konosuke Konishi and Matsuhiko Hayashi and Takao Saruta",
year = "1999",
language = "English",
volume = "22",
pages = "303--312",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis

AU - Nakaya, Hideaki

AU - Sasamura, Hiroyuki

AU - Kitamura, Yudai

AU - Amemiya, Tetsuro

AU - Konishi, Konosuke

AU - Hayashi, Matsuhiko

AU - Saruta, Takao

PY - 1999

Y1 - 1999

N2 - Angiotensin converting enzyme inhibitors (ACEI) are known to inhibit the progression of established renal failure. The aim of this study was to compare the efficacy of an ACEI and an AT1 receptor antagonist (AT1R-Ant) in preventing the development of renal disease, at an early stage of hypertensive nephrosclerosis. SHRSP/Izm rats (n = 61) were treated from 10 wk until 22 wk with the ACEI delapril (40 mg/kg/d) or the AT1R-Ant candesartan cilexetil (1 mg/kg/d). Proteinuria, and structural/ultrastructural changes were assessed at 14 and 22 wk. Treatment with either agent resulted in reductions in blood pressure and cardiovascular hypertrophy. Neither proteinuria nor major renal histological changes were evident at 14 wk. At 22 wk, however, proteinuria accompanied by nephrosclerotic changes was seen in the untreated SHRSP/Izm. Treatment with either ACEI or AT1R-Ant resulted in similar reductions in proteinuria (untreated, 32.2 ± 7.4; delapril-treated, 5.5 ± 1.2; candesartan-treated, 3.9 ± 0.3 mg/100 g/df. Prominent sclerosis of small-to-medium sized renal arteries was seen in the untreated SHRSP/Izm at 22 wk, but was similarly attenuated by the ACEI and AT1R-Ant. The glomerular ultrastructure was comparable between the two groups. No significant changes in renal AT1a or AT1b receptor subtype mRNA expression mere seen throughout the course of the study. In contrast, a decrease in AT2 receptor mRNA was seen in the drug-treated groups at 14 wk but not at 22 wk. These results suggest that both ACEI and AT1R-Ant have similar efficacy in attenuating the onset of renal injury in early hypertensive nephrosclerosis, and that treatment with either agent is associated with a transient decrease in AT2 receptor mRNA expression.

AB - Angiotensin converting enzyme inhibitors (ACEI) are known to inhibit the progression of established renal failure. The aim of this study was to compare the efficacy of an ACEI and an AT1 receptor antagonist (AT1R-Ant) in preventing the development of renal disease, at an early stage of hypertensive nephrosclerosis. SHRSP/Izm rats (n = 61) were treated from 10 wk until 22 wk with the ACEI delapril (40 mg/kg/d) or the AT1R-Ant candesartan cilexetil (1 mg/kg/d). Proteinuria, and structural/ultrastructural changes were assessed at 14 and 22 wk. Treatment with either agent resulted in reductions in blood pressure and cardiovascular hypertrophy. Neither proteinuria nor major renal histological changes were evident at 14 wk. At 22 wk, however, proteinuria accompanied by nephrosclerotic changes was seen in the untreated SHRSP/Izm. Treatment with either ACEI or AT1R-Ant resulted in similar reductions in proteinuria (untreated, 32.2 ± 7.4; delapril-treated, 5.5 ± 1.2; candesartan-treated, 3.9 ± 0.3 mg/100 g/df. Prominent sclerosis of small-to-medium sized renal arteries was seen in the untreated SHRSP/Izm at 22 wk, but was similarly attenuated by the ACEI and AT1R-Ant. The glomerular ultrastructure was comparable between the two groups. No significant changes in renal AT1a or AT1b receptor subtype mRNA expression mere seen throughout the course of the study. In contrast, a decrease in AT2 receptor mRNA was seen in the drug-treated groups at 14 wk but not at 22 wk. These results suggest that both ACEI and AT1R-Ant have similar efficacy in attenuating the onset of renal injury in early hypertensive nephrosclerosis, and that treatment with either agent is associated with a transient decrease in AT2 receptor mRNA expression.

KW - Angiotensin

KW - Nephrosclerosis

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=0032725656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032725656&partnerID=8YFLogxK

M3 - Article

C2 - 10580398

AN - SCOPUS:0032725656

VL - 22

SP - 303

EP - 312

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 4

ER -